Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
H9585 |
Povorcitinib |
1637677-22-5 | Povorcitinib is a potent and selective inhibitor of JAK1. Povorcitinib has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) . |
H9530 |
Atinvicitinib |
2169273-59-8 | Atinvicitinib is a selectivity,highly ligand efficient and efficacious Janus Kinase 1 inhibitor with IC50 value of 0.1 nM; Atinvicitinib has the potential for the research of atopic dermatitis . |
H9479 |
Ilunocitinib |
1187594-14-4 | Ilunocitinib is a potent Janus kinase inhibitor |
H9374 |
PF-06826647 |
2127109-84-4 | PF-06826647(Ropsacitinib) is an orally active and selective TYK2 inhibitor (IC50=17 nM), which binds to TYK2 catalytically active JH1 domain. PF-06826647 displays selectivity for TYK2 over JAK1 (IC50=383 nM) and JAK2 (74 nM);PF-06826647 can be used for the research of psoriasis, ulcerative colitis, and hidradenitis suppurativa. |
H9373 |
BMS-986202 |
1771691-34-9 | BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM; BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. |
H9249 |
NSC33994 |
82058-16-0 | NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC50 of 60 nM. |
H9248 |
ZM 449829 |
4452-06-6 | ZM 449829 is a potent, selective and ATP competitive inhibitor of JAK3, with a pIC50 of 6.8. ZM 449829 will be useful pharmacological tools for the investigation of the JAK3. |
H9188 |
Nezulcitinib |
2412496-23-0 | Nezulcitinib is a potent JAK kinase inhibitors for treatment of respiratory diseases. |
H8971 |
SHR-0302 sulfate |
1639419-51-4 | SHR0302 sulfate(Ivarmacitinib) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects. |
H8970 |
SHR-0302 |
1445987-21-2 | SHR0302(Ivarmacitinib) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. SHR0302 inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has anti-proliferative and anti-inflammatory effects. |
086-18516630705
sales@hmobio.com
1/F, building 4, No. 358-368, Kefu Road, Jiading District, Shanghai, China